Staphylococcus Infections Treatment Guidelines

Introduction to Staphylococcus Infections

The American College of Clinical Microbiology and Infectious Diseases recommends considering alternative options, such as anti-staphylococcal penicillins (e.g., oxacillin, nafcillin, dicloxacillin) or first-generation cephalosporins (e.g., cefazolin, cephalexin), for treating suspected Staphylococcus infections due to their effectiveness compared to ceftriaxone 1, 2

For MSSA infections, the Infectious Diseases Society of America recommends using dicloxacillin, cloxacillin, cephalexin, or oxacillin/nafcillin (IV) as treatment options, with a strength of evidence not specified 1, 2
For MRSA infections, the Infectious Diseases Society of America recommends using vancomycin, linezolid, clindamycin, daptomycin, or sulfamethoxazole-trimethoprim as treatment options, with a strength of evidence not specified 1, 2, 3
For MSSA infections, the Clinical Infectious Diseases society recommends using oxacillin or nafcillin plus rifampin, followed by rifampin plus a companion drug (typically ciprofloxacin), with a strength of evidence not specified 4
For MRSA infections, the Clinical Infectious Diseases society recommends using vancomycin plus rifampin, with a strength of evidence not specified 4

For device-related infections, ceftriaxone lacks the biofilm activity that makes rifampin combinations preferred, according to the Clinical Infectious Diseases society, with a strength of evidence based on expert opinion 4
The use of ceftriaxone in device-related infections is not recommended due to its limited biofilm activity, with a strength of evidence based on expert opinion 4
Combination therapy with rifampin is crucial for device-related infections due to its activity against biofilm organisms, with a strength of evidence based on expert opinion 4

Cephalosporins, such as ceftriaxone, should be avoided for methicillin-resistant strains due to cross-resistance, regardless of in vitro susceptibility results, based on high-quality evidence 5, 1, 2
Alternative options, such as anti-staphylococcal penicillins or first-generation cephalosporins, are recommended for treating suspected Staphylococcus infections due to their effectiveness compared to ceftriaxone, with a strength of evidence not specified 1, 2

For serious native tissue infections, the American Heart Association recommends oxacillin or nafcillin 8-12 g/24 h IV divided into 3-4 doses for at least 4 weeks, with a strength of evidence based on moderate-quality evidence 6
For less severe native tissue infections, oral options include dicloxacillin, cloxacillin, or cephalexin, although the strength of evidence for this is not specified 6
For prosthetic material/device-related infections, the American Heart Association recommends combination therapy, including oxacillin or nafcillin 8-12 g/24 h IV divided into 3-4 doses plus rifampin 900 mg/24 h IV or orally divided into three doses, both for 6-8 weeks, with a strength of evidence based on expert opinion 5, 7
For native valve infections, the American Heart Association recommends oxacillin or nafcillin IV for 4-6 weeks, with the addition of gentamicin for the first 3-5 days being optional but increasing the risk of toxicity, with a strength of evidence based on moderate-quality evidence 6, 5
For prosthetic valve infections, combination therapy with oxacillin or nafcillin plus rifampin for 6-8 weeks is recommended, with gentamicin added for the first 2 weeks if susceptible, based on moderate-quality evidence 5, 7

For patients with non-anaphylactic penicillin allergies, cefazolin is an appropriate alternative, according to the American Heart Association, with a strength of evidence based on expert opinion 5
For patients with severe penicillin allergies, vancomycin 30 mg/kg/24 h IV divided into two doses is recommended, based on moderate-quality evidence 7
Longer courses (4-6 weeks) of therapy are required for endocarditis, osteomyelitis, and prosthetic device infections, according to the American Heart Association, with a strength of evidence based on moderate-quality evidence 5
For the debridement and retention approach, initial IV therapy with oxacillin or nafcillin plus rifampin for 2-6 weeks, followed by oral rifampin plus a companion drug (ciprofloxacin preferred based on susceptibilities), is recommended, with a total duration of 3 months for hip and 6 months for knee, based on low-quality evidence 4